An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression

International Journal of Neuropsychopharmacology

Volumn 15, Issue 8, 2012, Pages 1063-1072

  Salvadore, Giacomo ^a   Van Der Veen, Jan Willem ^b   Zhang, Yan ^b   Marenco, Stefano ^c   MacHado Vieira, Rodrigo ^a,e   Baumann, Jacqueline ^a   Ibrahim, Lobna A ^a   Luckenbaugh, David A ^a   Shen, Jun ^b   Drevets, Wayne C ^b,d   Zarate, Carlos A ^a  

^a Department of Health and Human Services   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^e LIM27   (Brazil)

Author keywords

biomarkers; glutamate; glutamine; magnetic resonance spectroscopy (MRS); major depressive disorder (MDD)

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; KETAMINE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; FEMALE; GLIA; HUMAN; MAJOR DEPRESSION; MALE; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG DOSE; TREATMENT RESPONSE; VENTROMEDIAL PREFRONTAL CORTEX;

ADULT; CEREBRAL CORTEX; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; HUMANS; KETAMINE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES;

EID: 84864536412     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001593     Document Type: Article

References (44)

1. Alonso G (2000). Prolonged corticosterone treatment of adult rats inhibits the proliferation of oligodendrocyte progenitors present throughout white and gray matter regions of the brain. Glia 31, 219-231.
2. Autry AE, Adachi M, Nosyreva E, Na ES, et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95.
3. Banasr M, Duman RS (2007). Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS and Neurological Disorders Drug Targets 6, 311-320.
4. Bernard R, Kerman IA, Thompson RC, Jones EG, et al. (2011). Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Molecular Psychiatry 16, 634-646.
5. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, et al. (2008). Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. International Journal of Neuropsychopharmacology 11, 255-260.
6. Bonvento G, Sibson N, Pellerin L (2002). Does glutamate image your thoughts? Trends in Neuroscience 25, 359-364.
7. Choudary PV, Molnar M, Evans SJ, Tomita H, et al. (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences USA 102, 15653-15658.
8. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates.
9. D'Amelio F, Eng LF, Gibbs MA (1990). Glutamine synthetase immunoreactivity is present in oligodendroglia of various regions of the central nervous system. Glia 3, 335-341.
10. Deakin JF, Lees J, McKie S, Hallak JE, et al. (2008). Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Archives of General Psychiatry 65, 154-164.
11. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, et al. (2010). A randomized add-on trial of an N-methyl-Daspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67, 793-802.
12. Duman RS, Li N, Liu RJ, Duric V, et al. (2011). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35-41.
13. First M, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for the DSM-IV-TR Axis I Disorders-Patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute.
14. Hamidi M, Drevets WC, Price JL (2004). Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biological Psychiatry 55, 563-569.
15. Hamilton MC, Schutte NS, Malouff JM (1959). Hamilton Anxiety Scale (HAMA). In: Hamilton MC (Ed.), Source Book of Adult Assessment (Applied Clinical Psychology) (pp. 154-157). New York: Plenum Press.
16. Hasler G, van der Veen JW, Geraci M, Shen J, et al. (2009). Prefrontal cortical gamma-aminobutyric acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biological Psychiatry 65, 273-275.
17. Hasler G, van der Veen JW, Tumonis T, Meyers N, et al. (2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry 64, 193-200.
18. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, et al. (2004). Measurement of brain glutamate using TE-averaged PRESS at 3 T. Magnetic Resononance in Medicine 51, 435-440.
19. Homayoun H, Moghaddam B (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 27, 11496-11500.
20. Iltis I, Koski DM, Eberly LE, Nelson CD, et al. (2009). Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR in Biomedicine 22, 737-744.
21. Li N, Lee B, Liu RJ, Banasr M, et al. (2010). mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
22. Martinez-Hernandez A, Bell KP, Norenberg MD (1977). Glutamine synthetase: glial localization in brain. Science 195, 1356-1358.
23. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
24. Preskorn SH, Baker B, Kolluri S, Menniti FS, et al. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28, 631-637.
25. Price JL, Drevets WC (2010). Neurocircuitry of mood disorders. Neuropsychopharmacology 35, 192-216.
26. Rajkowska G, Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology in depression. CNS and Neurological Disorders-Drug Targets 6, 219-233.
27. Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, et al. (2007). GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 32, 471-482.
28. Rowland LM, Bustillo JR, Mullins PG, Jung RE, et al. (2005). Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. American Journal of Psychiatry 162, 394-396.
29. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, et al. (2009). Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biological Psychiatry 65, 289-295.
30. Salvadore G, Cornwell BR, Sambataro F, Latov D, et al. (2010). Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35, 1415-1422.
31. Salvadore G, Zarate CA (2010). Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine? Biological Psychiatry 68, 780-782.
32. Sanacora G, Kendell SF, Fenton L, Coric V, et al. (2004). Riluzole augmentation for treatment-resistant depression. American Journal of Psychiatry 161, 2132.
33. Sanacora G, Mason GF, Rothman DL, Krystal JH (2002). Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. American Journal of Psychiatry 159, 663-665.
34. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426-437.
35. Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants: 20 years on. Trends in Pharmacological Sciences 30, 563-569.
36. Stephenson MC, Gunner F, Napolitano A, Greenhaff PL, et al. (2011). Applications of multi-nuclear magnetic resonance spectroscopy at 7 T. World Journal of Radiology 3, 105-113.
37. Taylor MJ, Tiangga ER, Nmhuircheartaigh R, Cowen P (2011). Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. Journal of Psychopharmacology. Published online: 26 May 2011. doi :10.1177/0269881111405359.
38. Umhau JC, Momenan R, Schwandt ML, Singley E, et al. (2010). Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Archives of General Psychiatry 67, 1069-1077.
39. Valentine GW,Mason GF, Gomez R, Fasula M, et al. (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by (1)H-MRS. Psychiatry Research 191, 222-227.
40. Walter M, Henning A, Grimm S, Schulte RF, et al. (2009). The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Archives of General Psychiatry 66, 478-486.
41. Whalen PJ, Johnstone T, Somerville LH, Nitschke JB, et al. (2008). A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biological Psychiatry 63, 858-863.
42. Zarate CA, Payne JL, Quiroz J, Sporn J, et al. (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry 161, 171-174.
43. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.
44. Zhang Y, Marenco S, Shen J (2007). Correction of frequency and phase variations induced by eddy currents in localized spectroscopy with multiple echo times. Magnetic Resonance in Medicine 58, 174-178.